Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lilia Pineda"'
Autor:
Eric F Morand, Richard A Furie, Ian N Bruce, Edward M Vital, Maria Dall'Era, Emmanuelle Maho, Lilia Pineda, Raj Tummala
Publikováno v:
The Lancet Rheumatology. 4:e282-e292
Autor:
Gabriel Abreu, Lilia Pineda, David A. Isenberg, Ronald F van Vollenhoven, Ian N. Bruce, Richard Furie, Eric F Morand, Raj Tummala
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology (Hoboken, N.J.), 73(11), 2059-2068. John Wiley and Sons Ltd
Arthritis & rheumatology (Hoboken, N.J.), 73(11), 2059-2068. John Wiley and Sons Ltd
Objective: The British Isles Lupus Assessment Group–based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials. To understand the relevance of BICLA in clinical
Autor:
Richard Furie, Lilia Pineda, Raj Tummala, Rubana N Kalyani, Gabriel Abreu, Eric F Morand, M Alex Michaels
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss 1 (2021)
Lupus Science & Medicine
Lupus Science & Medicine
ObjectiveIn phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using dat
Autor:
Joan T. Merrill, Eric F Morand, Edward M Vital, Rubana N Kalyani, Raj Tummala, Lilia Pineda, Gabriel Abreu, Anca Askanase, Richard Furie
Publikováno v:
Lupus. 30(8)
BackgroundSystemic lupus erythematosus (SLE) management objectives include preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the phase 3 TULIP-1 and TULIP-2 trials in patients with moderate to severe SLE were analyz
Autor:
Raj Tummala, Eric F Morand, Lilia Pineda, Yoshiya Tanaka, Richard Furie, Rubana N Kalyani, Gabriel Abreu
Publikováno v:
Oral presentations.
Background Treatment of patients with SLE with anifrolumab resulted in higher BICLA response rates vs placebo at Week 52 in the phase 3 trials, TULIP-2 (16.3% difference; Morand et al, 2020) and TULIP-1 (16.4% difference; Furie et al, 2019). We evalu
Autor:
Anca Askanase, Gabriel Abreu, Eric F Morand, Rubana N Kalyani, E.M. Vital, Raj Tummala, Richard Furie, Lilia Pineda
Publikováno v:
Oral presentations.
Background Anifrolumab treatment improved BICLA response rates in patients with SLE in the phase 3 TULIP-2 and TULIP-1 trials (Morand et al, 2020; Furie et al, 2019). In addition, annualized flare rates were lower with anifrolumab vs placebo. TULIP-2
Autor:
Rubana N Kalyani, Ian N. Bruce, Eric F Morand, Lilia Pineda, Richard Furie, Kenneth C. Kalunian, Gabriel Abreu, Raj Tummala
Publikováno v:
Poster presentations.
Background In the phase 3 TULIP-2 and TULIP-1 trials in SLE, anifrolumab treatment increased the percentages of patients with BICLA responses vs placebo at Week 52 (Morand et al, 2020; Furie et al, 2019). To better understand the time course of BICLA
Autor:
Tulip Trial Investigators, Christophe Richez, Philip Z Brohawn, Anna Berglind, Raj Tummala, Yoshiya Tanaka, Ian N. Bruce, Lilia Pineda, Richard Furie, Sang Cheol Bae, Anca Askanase, Eric F Morand
Publikováno v:
Morand, E F, Furie, R, Tanaka, Y, Bruce, I N, Askanase, A D, Richez, C, Bae, S, Brohawn, P Z, Berglind, A & Tummala, R 2020, ' Trial of Anifrolumab in Active Systemic Lupus Erythematosus ', New England Journal Of Medicine, vol. 382, no. 3, pp. 211-221 . https://doi.org/10.1056/NEJMoa1912196
BACKGROUNDAnifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9757c1d3f7e5b8f10bdf52df24b23ae8
https://pure.manchester.ac.uk/ws/files/157208707/nejmoa1912196.pdf
https://pure.manchester.ac.uk/ws/files/157208707/nejmoa1912196.pdf
Autor:
Kenneth C. Kalunian, Ian N. Bruce, Gabriel Abreu, Raj Tummala, Richard Furie, Eric F Morand, Rubana N Kalyani, Lilia Pineda
Publikováno v:
Annals of the Rheumatic Diseases. 79:2.1-3
Background:In the phase 3 TULIP-2 and TULIP-1 trials in SLE, treatment with the type I interferon receptor antibody anifrolumab resulted in higher percentages of patients with BICLA responses vs placebo at Week 52, with differences of 16.3% (primary
Autor:
Raj Tummala, Anca Askanase, Gabriel Abreu, Lilia Pineda, E.M. Vital, Rubana N Kalyani, Eric F Morand, Richard Furie
Publikováno v:
Annals of the Rheumatic Diseases. 79:1028.1-1029
Background:Anifrolumab treatment resulted in improved British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA) response rates in patients with systemic lupus erythematosus (SLE) in the phase 3 TULIP-2 and TULIP-1 trials